Literature DB >> 24088276

Identifiable hypertension: a new spectrum.

Lawrence R Krakoff1.   

Abstract

Identifiable hypertension now encompasses a large and growing spectrum of disorders from the most common associations (eg, diabetes), to rare genetic disorders and adverse reactions (eg, hypertension caused by anti- VEGF cancer therapy). Each of these disorders requires strategies for diagnosis and management that extend well beyond the usual treatment of hypertension for maximal benefit in preventing cardiovascular disease.

Entities:  

Mesh:

Year:  2013        PMID: 24088276      PMCID: PMC8033801          DOI: 10.1111/jch.12153

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  41 in total

1.  Primary aldosteronism, diagnosed by the aldosterone to renin ratio, is a common cause of hypertension.

Authors:  Pitt O Lim; Thomas M MacDonald
Journal:  Clin Endocrinol (Oxf)       Date:  2003-10       Impact factor: 3.478

Review 2.  Monogenic low renin hypertension.

Authors:  Maria I New; David S Geller; Francesco Fallo; Robert C Wilson
Journal:  Trends Endocrinol Metab       Date:  2005-04       Impact factor: 12.015

3.  Treatment of bevacizumab-induced hypertension by amlodipine.

Authors:  Olivier Mir; Romain Coriat; Stanislas Ropert; Laure Cabanes; Benoit Blanchet; Sandra Camps; Bertrand Billemont; Bertrand Knebelmann; François Goldwasser
Journal:  Invest New Drugs       Date:  2010-09-29       Impact factor: 3.850

4.  Licorice-induced hypermineralocorticoidism.

Authors:  R V Farese; E G Biglieri; C H Shackleton; I Irony; R Gomez-Fontes
Journal:  N Engl J Med       Date:  1991-10-24       Impact factor: 91.245

5.  Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study.

Authors:  Stella Douma; Konstantinos Petidis; Michael Doumas; Panagiota Papaefthimiou; Areti Triantafyllou; Niki Kartali; Nikolaos Papadopoulos; Konstantinos Vogiatzis; Chrysanthos Zamboulis
Journal:  Lancet       Date:  2008-06-07       Impact factor: 79.321

Review 6.  Bevacizumab-induced hypertension: pathogenesis and management.

Authors:  Kostas N Syrigos; Eleni Karapanagiotou; Paraskevi Boura; Christian Manegold; Kevin Harrington
Journal:  BioDrugs       Date:  2011-06-01       Impact factor: 5.807

7.  Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis.

Authors:  A G Johnson; T V Nguyen; R O Day
Journal:  Ann Intern Med       Date:  1994-08-15       Impact factor: 25.391

Review 8.  Contraceptive hormone use and cardiovascular disease.

Authors:  Chrisandra L Shufelt; C Noel Bairey Merz
Journal:  J Am Coll Cardiol       Date:  2009-01-20       Impact factor: 24.094

9.  Renin secreting tumors: diagnosis, conservative surgical approach and long-term results.

Authors:  F Haab; J M Duclos; T Guyenne; P F Plouin; P Corvol
Journal:  J Urol       Date:  1995-06       Impact factor: 7.450

10.  Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.

Authors:  Michael L Maitland; George L Bakris; Henry R Black; Helen X Chen; Jean-Bernard Durand; William J Elliott; S Percy Ivy; Carl V Leier; Joann Lindenfeld; Glenn Liu; Scot C Remick; Richard Steingart; W H Wilson Tang
Journal:  J Natl Cancer Inst       Date:  2010-03-29       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.